WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
US restricts trade with companies tied to drones used by Russia, Houthis
Watch live: Millions across North America await total solar eclipse
Russia hits vast dam in war's largest strike on Ukrainian energy infrastructure, Kyiv says
Refugee agency chief warns that the number of Syrians leaving Lebanon is likely to rise
HK gov't declines to say how much funding it gave for 'Chubby Hearts'
US defense chief denies genocide committed in Gaza
Rhod Gilbert shares cancer update as he admits he's 'pinching himself' over performing stand
US restricts trade with companies tied to drones used by Russia, Houthis
Box office: ‘Challengers’ scores with $15 million in ticket sales
HK gov't declines to say how much funding it gave for 'Chubby Hearts'